BioSpace News Archive

Rakuten Medical, Inc. (Rakuten Medical) today announced the results of two preclinical studies presented at the American Association for Cancer Research (AACR) Virtual Meeting II. These studies further demonstrate t

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced a poster presentation at

Eighty-five million U.S. consumers managing food allergies spend more than $19 billion annually on specialty food products to avoid allergic reactions or other health consequences—paying five percent more per month than the average consumer—according to new research released from FARE, the largest private funder of food allergy research in the world.

New Data Highlights the Flexibility of OncoSec’s Therapeutic Platform to Enable Greater Anti-Tumor Activity with the Next-Generation TAVO PLUS IL-12 Plasmid PENNINGTON, N.J. and SAN DIEGO , June 22, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (the “Company” or “OncoSec”) (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today p

Minerva Biotechnologies (Minerva) today announced that it has licensed from Memorial Sloan Kettering Cancer Center (MSK) “1XX” technology for use with Minerva’s proprietary anti-MUC1* antibodies to increase CAR T cell persistence in patients. “This promises to be a great step forward for CAR T cell treatment of solid tumors,” said Minerva CEO Dr. Cynthia Bamdad. “We are combining Minerva’s demonstrated cancer-specific

Study reinforces that remote health monitoring devices hold strong potential to reduce patient burdens and healthcare costs

RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today it is presenting an abstract on RGX-019, RGENIX’s pre-clinical antibody program in development. RGENIX’s abstract, “In Vivo Safety and Efficacy of RGX-019, a MerTK Targeting Monoclonal Antibody” was accepted for the 2020 American Association for Cancer Research (AACR) Annual Meeting

Data include largest cohort of breast cancer samples ever evaluated in this context and demonstrate that high levels of galectin-9 are associated with shorter time to disease relapse Wholly-owned novel monoclonal antibody (LYT-200) is designed to selectively inhibit galectin-9, with a first-in-human clinical trial expected to begin in 2H 2020 BOSTON--( BUSINESS WIRE )-- PureTech Health plc (LSE: PRTC) (“PureTech” or the “Company”), a clinic

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, announced today that data from clinical studies on their oncolytic agent, CAL1 vaccinia virus, and stem cell delivery system will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting II, which will be held in virtual format June 22 through June 24, 2020,

Next Generation FRα-Targeting ADC Engineered to Maximize Potential Clinical Benefit for Patients with Lower FRα Expression Potent Anti-Tumor Activity Exhibited in Ovarian Cancer and Other Tumor Types Regardless of FRα Expression Level